| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
3,4-MethylenedioxyPV9 hydrochloride targets monoamine transporters, particularly the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT), similar to other pyrovalerone derivatives. By inhibiting reuptake of these neurotransmitters, it increases synaptic concentrations of dopamine, norepinephrine, and serotonin, leading to psychostimulant effects. The exact binding affinities for this specific analogue have not been fully characterized, but structure-activity studies suggest potent DAT inhibition with varying selectivity over SERT based on alkyl chain length.
|
|---|---|
| ln Vitro |
In vitro, 3,4-MethylenedioxyPV9 hydrochloride demonstrates concentration-dependent cytotoxicity across multiple human cell lines. It is toxic to BEAS-2B (bronchial epithelial cells), human aortic endothelial cells (HAE), HASM (airway smooth muscle), SK-N-SH (neuroblastoma), A172 (glioblastoma), HepG2 (hepatocellular carcinoma), MKN45 (gastric cancer), and DLD1 (colorectal cancer) cells, with LC50 values ranging from 12.8 to 67.5 microM. First-generation pyrovalerones including related compounds produce modest decreases in mitochondrial activity at lower concentrations than methamphetamine in examined cell lines.
|
| ln Vivo |
In vivo activity data for 3,4-MethylenedioxyPV9 hydrochloride are extremely limited, as this compound is primarily an analytical standard and forensic research tool rather than a therapeutic candidate. Based on its structural similarity to known pyrovalerone derivatives such as MDPV and pyrovalerone, it is presumed to produce psychostimulant effects including increased locomotor activity, stereotypy, hyperthermia, and cardiovascular stimulation in animal models. These effects are typically mediated through inhibition of dopamine and norepinephrine reuptake, with potency correlated to alkyl chain structure.
|
| Enzyme Assay |
Due to the compound's status as an analytical standard and research chemical rather than a drug candidate, standardized cell-free enzyme/receptor binding protocols are not publicly available. However, typical protocols for pyrovalerone derivatives involve competitive binding assays using membrane preparations from cells expressing human DAT, NET, or SERT, incubated with [3H]-WIN35,428 or [3H]-dopamine in the presence of varying inhibitor concentrations, followed by filtration and scintillation counting to determine Ki values.
|
| Cell Assay |
Cytotoxicity protocol: Human cell lines (e.g., HepG2, BEAS-2B, SK-N-SH, DLD1) are seeded in 96-well plates at appropriate densities and cultured overnight. Cells are treated with 3,4-MethylenedioxyPV9 hydrochloride at concentrations ranging from 1 microM to 200 microM (typical range covering LC50 values of 12.8-67.5 microM) for 24-72 hours. Cell viability is assessed using MTT, XTT, or WST-1 assays according to manufacturer protocols. Absorbance is measured at 450-570 nm, and LC50 values are calculated by nonlinear regression analysis.
|
| Animal Protocol |
In vivo animal studies for this specific analogue are not typically conducted due to its forensic and analytical nature. For related pyrovalerone derivatives, standard protocols involve administration to male Sprague-Dawley rats or mice via intraperitoneal or subcutaneous injection at doses ranging from 0.1-10 mg/kg. Locomotor activity is monitored using photobeam chambers, body temperature via telemetry probes, and stereotyped behaviors are scored by blinded observers. Plasma and brain concentrations are quantified by LC-MS/MS to establish pharmacokinetic-pharmacodynamic relationships.
|
| ADME/Pharmacokinetics |
Limited pharmacokinetic information is available for this specific compound. As a synthetic cathinone, it is expected to exhibit moderate to high lipophilicity (predicted logP ~4-5) due to the octyl chain, leading to extensive tissue distribution and potential accumulation in lipid-rich compartments including brain. Metabolism likely involves N-dealkylation, ketone reduction, and aromatic hydroxylation mediated by CYP450 enzymes, followed by glucuronidation or sulfation prior to urinary excretion. Based on analogue data, plasma half-life in rodents may range from 1-4 hours.
|
| Toxicity/Toxicokinetics |
Toxicity data for 3,4-MethylenedioxyPV9 hydrochloride are primarily from in vitro cytotoxicity studies. The compound shows broad-spectrum cytotoxic activity across multiple cell types with LC50 values from 12.8 to 67.5 microM, indicating moderate to high cellular toxicity. Based on related pyrovalerones, in vivo toxicity may include hyperthermia, seizures, rhabdomyolysis, cardiovascular collapse, hepatotoxicity, and neurotoxicity at high doses. Long-term effects may include dopaminergic terminal damage and cognitive impairment.
|
| References |
[1]. Toshiyuki Matsunaga, et al. Structure-activity relationship for toxicity of α-pyrrolidinophenones in human aortic endothelial cells.
|
| Additional Infomation |
3,4-MethylenedioxyPV9 hydrochloride is not a pharmaceutical and has no clinical applications or regulatory approval. It is a research chemical and analytical standard used for forensic identification, toxicological analysis, and structure-activity relationship studies of synthetic cathinones. The compound is categorized as a controlled substance or analogue in many jurisdictions due to its structural similarity to MDPV and other pyrovalerones. It is supplied as a hydrochloride salt for stability and solubility. Not for human consumption.
|
| Molecular Formula |
C19H28CLNO3
|
|---|---|
| Molecular Weight |
353.883524894714
|
| Exact Mass |
353.175
|
| CAS # |
24646-40-0
|
| PubChem CID |
132989256
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
24
|
| Complexity |
381
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(N1CCCC1)(CCCCCC)C(C1C=CC2OCOC=2C=1)=O.Cl
|
| InChi Key |
PYKXCYXCXKRYNZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H27NO3.ClH/c1-2-3-4-5-8-16(20-11-6-7-12-20)19(21)15-9-10-17-18(13-15)23-14-22-17;/h9-10,13,16H,2-8,11-12,14H2,1H3;1H
|
| Chemical Name |
1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yloctan-1-one;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (70.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.25 mg/mL (3.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8258 mL | 14.1291 mL | 28.2582 mL | |
| 5 mM | 0.5652 mL | 2.8258 mL | 5.6516 mL | |
| 10 mM | 0.2826 mL | 1.4129 mL | 2.8258 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
